Jay K Staas

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents, primarily in Biopharmaceutical Delivery. Top assignees: Southern Research Institute, The UAB Research Foundation (The University of Alabama at Birmingham), Clinuvel Pharmaceuticals Limited. Active years: 1991-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jay K Staas. Retrieved from https://idiyas.com/inventor/jay-k-staas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.8

ph-index = 10

Forward Citations = 1,238(Granted Patents)

Location History:

Birmingham, AL (US) (1991 - 2000)
Alabaster, AL (US) (2001 - 2009)
Madison, AL (US) (2013)
Marylene, AL (US) (2018)
Maylene, AL (US) (2016 - 2020)

Company Filing History:

10 out of 205

Southern Research Institute

patents

7 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

3 out of 8

Clinuvel Pharmaceuticals Limited

patents

4. 1 out of 1

Brookwood Pharmaceuticals, Inc.

6. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2020

Loading Chart...

Areas of Expertise:

Melanogenesis

Microparticle Compositions

Bioactive Agents

Immune Response

Opioid Antagonist

Intracellular Infections

Vaccines

Drug Delivery

Substance Abuse

Naltrexone

Methadone

Buprenorphine

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10857208 - Methods of inducing melanogenesis in a subject (2020-12-08),

2. 10076555 - Methods of inducing melanogenesis in a subject (2018-09-18),

3. 9345911 - Methods of inducing melanogenesis in a subject (2016-05-24),

4. 8541028 - Methods for manufacturing delivery devices and devices thereof (2013-09-24),

5. 7473431 - Injectable methadone, methadone and naltrexone, or buprenorphine and naltrexone microparticle compositions and their use in reducing consumption of abused substances (2009-01-06),

6. 6495155 - Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances (2002-12-17),

7. 6312731 - Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof (2001-11-06),

8. 6306425 - Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol (2001-10-23),

9. 6264991 - Compositions and methods for treating intracellular infections (2001-07-24),

10. 6024983 - Composition for delivering bioactive agents for immune response and its (2000-02-15),

11. 5942252 - Method for delivering bioactive agents into and through the (1999-08-24),

12. 5853763 - Method for delivering bioactive agents into and through the (1998-12-29),

13. 5820883 - Method for delivering bioactive agents into and through the (1998-10-13),

14. 5814344 - Method for delivering bioactive agents into and through the mucosally (1998-09-29),

15. 5811128 - Method for oral or rectal delivery of microencapsulated vaccines and (1998-09-22),

Title: The Innovative Mind of Jay K Staas

Introduction

Jay K Staas, a prolific inventor from Maylene, AL, has made significant contributions to the field of science and technology. With a remarkable portfolio of 16 patents, he has demonstrated a profound ability to innovate and advance knowledge in his areas of expertise.

Latest Patents

Among his latest inventions, two notable patents stand out. Both patents pertain to the "Methods of inducing melanogenesis in a subject." These patents describe methods and compositions for inducing melanogenesis in humans. The innovative method involves administering an alpha-MSH analogue in an effective amount and time to induce melanogenesis by the melanocytes in the epidermal tissue of the subject without causing homologous desensitization of melanocortin-1 receptors.

Career Highlights

Throughout his career, Staas has worked with esteemed organizations such as Southern Research Institute and the UAB Research Foundation. His roles within these institutions have allowed him to explore and develop cutting-edge technologies that contribute to advancements in health and science.

Collaborations

Jay K Staas has collaborated with notable individuals, including Thomas R. Tice and Richard M. Gilley. These collaborations have fostered a rich exchange of ideas and expertise, further bolstering Staas's innovative capabilities.

Conclusion

Jay K Staas exemplifies the spirit of innovation, continuously striving to push the boundaries of knowledge with his inventions. His contributions in the realm of melanogenesis and beyond reflect his commitment to enhancing human health through scientific discovery. As his career progresses, the impact of his work will undoubtedly be felt in various fields.

Profile summary based on public USPTO records.